Although the SUSTAIN-6 trial illustrates that diabetic patients taking subcutaneous semaglutide are not at increased risk of developing acute pancreatitis, clinicians may need to consider discontinuation of this GLP-1 receptor agonist in patients who present with AP while taking this class of medication, particularly if they have other risk factors for acute pancreatitis
Push the syringe to release the bubbles back into the vial
[DOI] [PubMed] [Google Scholar] 756.Wadden TA, Hollander P, Klein S, et al
To protect against photodegradation, pharmaceutical-grade Semaglutide Powder should be stored in amber glass vials or aluminum foil-lined containers that block light penetration
Brookshire: And theyre also at much higher doses, so theyre hammering that receptor much harder than the natural GLP-1 that you might produce
In one clinical trial, people taking the 2.4 mg dose of Wegovy lost nearly 10% of their body weight after 28 weeks